Trial results
$VERA — atacicept
Vera Therapeutics, Inc. (VERA) atacicept: trial results in IgA nephropathy (IgAN) and other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD), 2026.
The catalyst
"In the Phase 2 PIONEER clinical trial, for which we expect to report additional results in the fourth quarter of 2026, we are evaluating atacicept in a broader population of IgAN patients as well as other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), in patients with anti-phospholipase A2 receptor or anti-nephrin autoantibodies."
— Vera Therapeutics, Inc., 10-Q filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
VERA-ATACICEPT-2026- Company
- Vera Therapeutics, Inc.
- Kind
- Trial results
- Indication
- IgA nephropathy (IgAN) and other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD)
- Window
- 2026-01-01 – 2026-12-31
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.